Wendy S. Johnson - 14 Jul 2021 Form 4 Insider Report for Reneo Pharmaceuticals, Inc. (OKUR)

Reporting relationship: Chief Development Officer
Issuer ticker: OKUR
Reported as of: 14 Jul 2021
Net transaction value: -$949,756
SEC form: 4
Accepted by SEC: 15 Jul 2021, 17:33:47 UTC
Prior SEC filing: 09 Jul 2021
Next SEC filing: 07 Sep 2021
Source filing: View source filing
Reporting owner signature: /s/ Vineet R. Jindal, Attorney-in-Fact

Key filing fact

Wendy S. Johnson filed Form 4 for Reneo Pharmaceuticals, Inc. (OKUR) on 15 Jul 2021.

Key facts

This page summarizes Wendy S. Johnson's Form 4 filing for Reneo Pharmaceuticals, Inc. (OKUR).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 15 Jul 2021, 17:33.

Change

Previous filing in this sequence was filed on 09 Jul 2021.
Current net transaction value: -$949,756.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RPHM transaction

Common Stock

Sale

Transaction value: $949,756
Shares: -111,736
Change %: -100%
Price: $8.50
Shares after: 0
Date: 14 Jul 2021
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The Reporting Person previously notified the Issuer of her intention to retire from her position as the Issuer's Chief Development Officer, effective on or before December 31, 2021. Following her announcement, the Reporting Person exercised an option totaling 111,736 shares of Common Stock of the Issuer (the "Shares") on July 8, 2021. The Reporting Person is selling the Shares privately to Abingworth Bioventures 8 LP ("Abingworth"), an existing stockholder of the Issuer. Bali Muralidhar, a Director of the Issuer, is a member of the investment committee of Abingworth.